CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphoma
暂无分享,去创建一个
W. Chan | K. Fu | J. Vose | Y. Oki | H. Kantarjian | Xuelin Huang | Koichi Takahashi | M. Keating | S. O'brien | L. Kwak | J. Burger | W. Wierda | L. Fayad | S. Neelapu | Lianchun Xiao | R. Davis | M. Fanale | F. Hagemeister | J. Romaguera | F. Samaniego | N. Fowler | M. Sivina | J. Hoellenriegel | Julia Hoellenriegel
[1] S. Swerdlow. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues , 2017 .
[2] J Carl Barrett,et al. Reproducible, Quantitative, and Flexible Molecular Subtyping of Clinical DLBCL Samples Using the NanoString nCounter System , 2014, Clinical Cancer Research.
[3] J. Byrd,et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. , 2014, The New England journal of medicine.
[4] G. Salles,et al. PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma. , 2014, The New England journal of medicine.
[5] A. Zelenetz,et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. , 2014, The New England journal of medicine.
[6] W. Wilson,et al. Treatment strategies for aggressive lymphomas: what works? , 2013, Hematology. American Society of Hematology. Education Program.
[7] Michael L. Wang,et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. , 2013, The New England journal of medicine.
[8] Juthamas Sukbuntherng,et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. , 2013, The New England journal of medicine.
[9] N. Chiorazzi,et al. The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. , 2012, Blood.
[10] M. Keating,et al. The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. , 2011, Blood.
[11] A. Rosenwald,et al. CCL3 (MIP-1α) plasma levels and the risk for disease progression in chronic lymphocytic leukemia. , 2011, Blood.
[12] Richard Sherry,et al. The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. , 2011, Blood.
[13] Ronald Levy,et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. , 2010, Blood.
[14] D. Homann,et al. Comprehensive assessment of chemokine expression profiles by flow cytometry. , 2010, The Journal of clinical investigation.
[15] Jan Delabie,et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma , 2010, Nature.
[16] A. Rosenwald,et al. High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation. , 2007, Blood.
[17] Andrew Lister,et al. Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications--a study from the Lunenburg Lymphoma Biomarker Consortium. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] Grégoire Altan-Bonnet,et al. Chemokines enhance immunity by guiding naive CD8+ T cells to sites of CD4+ T cell–dendritic cell interaction , 2006, Nature.
[19] Ash A. Alizadeh,et al. Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. , 2004, The New England journal of medicine.
[20] L. Staudt,et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. , 2002, The New England journal of medicine.
[21] Varuna Aluvihare,et al. B cells and professional APCs recruit regulatory T cells via CCL4 , 2001, Nature Immunology.
[22] L. Staudt,et al. BCL-6 represses genes that function in lymphocyte differentiation, inflammation, and cell cycle control. , 2000, Immunity.
[23] Ash A. Alizadeh,et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.
[24] A. Foussat,et al. Antigen Receptor Engagement Selectively Induces Macrophage Inflammatory Protein-1α (MIP-1α) and MIP-1β Chemokine Production in Human B Cells , 1999, The Journal of Immunology.
[25] Jeffrey A Jones,et al. Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial. , 2014, The Lancet. Oncology.
[26] R. Advani,et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] L. Staudt,et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. , 2004, Blood.
[28] Todd,et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning , 2002, Nature Medicine.
[29] A. Foussat,et al. Antigen receptor engagement selectively induces macrophage inflammatory protein-1 alpha (MIP-1 alpha) and MIP-1 beta chemokine production in human B cells. , 1999, Journal of immunology.